Choi Soon Min, Kim Dong Gyu, Lee Ji-Eun, Ho Joon, Kim Jin Kyong, Lee Cho Rok, Kang Sang-Wook, Lee Jandee, Jeong Jong Ju, Chung Woong Youn, Nam Kee-Hyun
Department of Surgery, Gwangmyeong Chung-Ang Hospital, Chung-Ang University College of Medicine, Seoul, South Korea.
Department of Surgery, Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Gland Surg. 2022 Sep;11(9):1451-1463. doi: 10.21037/gs-22-158.
It is difficult to reliably distinguish between American Thyroid Association (ATA) low-risk and intermediate-risk differentiated thyroid cancer (DTC) before surgery. Therefore, physicians are faced with a dilemma regarding the necessity and timing of completion total thyroidectomy (CT) after thyroid lobectomy (TL). We evaluated proper surgical methods by analyzing oncologic outcomes of TL in patients with DTC whose risk had been upgraded after surgery.
We retrospectively reviewed the medical records of 1,702 patients with DTC who underwent TL and ipsilateral central lymph node (LN) dissection between January 2006 and December 2011. The patients were classified into Group A (n=1,159; low risk; ≤5 central LN metastases or the absence of pathologic microscopic capsular invasion) and Group B (n=543; upgraded intermediate risk after surgery; >5 central LN metastases or the presence of pathologic microscopic capsular invasion). We analyzed their clinicopathological characteristics and recurrence-free survival.
All 32 patients who experienced recurrence underwent CT. After the first operation, the duration until reoperation in Groups A and B were 8.00±2.74 (range, 3.42-12.17) and 5.10±3.09 (range, 1.25-11.67) years, respectively. There was no significant difference in recurrence rates, disease-related mortality rates, or 10-year recurrence-free survival rates between the two groups. The mean follow-up durations in Groups A and B were 10.22±1.58 and 10.13±1.47 years, respectively. Univariate analysis showed that sex, age, tumor size, multifocality, extrathyroidal extension (ETE), and number of central LN metastases were not associated with recurrence after TL, although the rate of central LN metastases was. Multivariate analysis showed that sex, age, tumor size, multifocality, ETE, central LN metastases, and the number of central LN metastases were not associated with recurrence after TL, although multifocality was.
TL with prophylactic central compartment neck dissection (CCND) is sufficient for patients with DTC whose risk is upgraded after surgery because they have a good prognosis at long-term follow-up. Larger-scale randomized clinical trials are required to confirm our findings.
术前很难可靠地区分美国甲状腺协会(ATA)低风险和中风险的分化型甲状腺癌(DTC)。因此,医生在甲状腺叶切除术(TL)后完成全甲状腺切除术(CT)的必要性和时机上面临两难境地。我们通过分析术后风险升级的DTC患者TL的肿瘤学结局来评估合适的手术方法。
我们回顾性分析了2006年1月至2011年12月期间接受TL和同侧中央淋巴结(LN)清扫的1702例DTC患者的病历。患者分为A组(n = 1159;低风险;≤5个中央LN转移或无病理显微镜下包膜侵犯)和B组(n = 543;术后风险升级为中风险;>5个中央LN转移或存在病理显微镜下包膜侵犯)。我们分析了他们的临床病理特征和无复发生存率。
所有32例复发患者均接受了CT。首次手术后,A组和B组再次手术的时间分别为8.00±2.74(范围3.42 - 12.17)年和5.10±3.09(范围1.25 - 11.67)年。两组之间的复发率、疾病相关死亡率或10年无复发生存率无显著差异。A组和B组的平均随访时间分别为10.22±1.58年和10.13±1.47年。单因素分析显示,性别、年龄、肿瘤大小、多灶性、甲状腺外侵犯(ETE)和中央LN转移数量与TL术后复发无关,尽管中央LN转移率有关。多因素分析显示,性别、年龄、肿瘤大小、多灶性、ETE、中央LN转移及中央LN转移数量与TL术后复发无关,尽管多灶性有关。
对于术后风险升级的DTC患者,TL联合预防性中央区颈淋巴结清扫(CCND)就足够了,因为他们在长期随访中有良好的预后。需要更大规模的随机临床试验来证实我们的发现。